PBTC-N11: Immunologic Profiles of Patients with Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy.
What is the purpose of this study?
This research study is studying biomarkers in blood samples from young patients with newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy
Who can participate?
Patients between the ages of 4 and 21 who meet the following criteria can participate in this study:
DISEASE CHARACTERISTICS (meets one of the following criteria):
- Histologically confirmed posterior fossa tumor
- Newly diagnosed disease
- Medulloblastoma OR non-medulloblastoma (pilocytic astrocytoma, ependymoma, atypical rhabdoid tumor, or others)
- Scheduled to undergo craniotomy and tumor resection
- Chiari malformation
- Requires craniectomy for decompression
- No secondary decompression
- No unexplained febrile illness
- No active infection
- No autoimmune disorders such as inflammatory bowel disease, juvenile rheumatoid arthritis, or systemic lupus erythematosus
- No other immunosuppressive disorders (e.g., HIV infection)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Cancer - Brain and Spinal Tumors
What is involved?
Patients with Chiari malformation and patients with posterior fossa tumor undergo standard surgery. Patients with posterior fossa tumor also receive standard radiotherapy and chemotherapy.
Blood samples are collected at baseline and periodically to measure the level of circulating T-regulatory cells.